Why Did Sonnet BioTherapeutics Holdings Soar 11.49%?

On August 11, 2025, Sonnet BioTherapeutics Holdings, Inc. (SONN) experienced a significant surge in its stock price, rising by 11.49% in pre-market trading, indicating strong investor interest and confidence in the company's prospects.

Sonnet BioTherapeutics is a biotechnology company that specializes in developing biologic medicines with single or bifunctional actions. This focus on innovative therapeutic solutions has positioned the company as a key player in the biotech industry, attracting attention from investors and analysts alike.

Despite the competitive landscape, which includes companies like Ovid Therapeutics, Enlivex Therapeutics, and Karyopharm Therapeutics, Sonnet BioTherapeutics has managed to carve out a niche for itself. The company's unique platform for biologic medicines sets it apart from its competitors, offering potential for groundbreaking treatments in various therapeutic areas.

Sonnet BioTherapeutics' stock has also been noted for its high short interest, with a significant percentage of its shares being shorted. This indicates that while there is skepticism among some investors, there is also a strong belief in the company's potential for growth and success.